Loading
A phase 1/2 trial of Venetoclax and Azacitidine in acute myeloid leukaemia, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and myelodysplastic syndromes / neoplasms, run by Ellipses Pharma, now recruiting.
Study to Evaluate the Safety and Tolerability of EP0042 is a phase 1/2 interventional study registered as NCT04581512 by Ellipses Pharma, with 70 participants planned, started 2020-11-02 and due to reach its primary completion in 2027-12. Interventions recorded: EP0042, Venetoclax and Azacitidine (AZA).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/